Earnings Call · Q1 FY2022·2022-05-04

Q1 22EPS +17.24%·Rev n/aQ4 21EPS +16.85%·Rev n/aQ3 21EPS +54.63%·Rev n/aQ2 21EPS +45.68%·Rev n/a⚠ consensus missing

REGENERON PHARMACEUTICALS, INC. REGN

Ryan Crowe — Vice President, Investor Relations

Leonard Schleifer — Co-Founder, President and Chief Executive Officer

George Yancopoulos — President and Chief Scientific Officer

Marion McCourt — Executive Vice President, Commercial

Robert Landry — Executive Vice President, Chief Financial Officer

+0.1%1d on move date−3.0% vs SPY3d−5.7%5d−6.9%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more REGN calls or request research access.

More REGN calls Browse calls Request research access